Latest BDSX news

Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings

GlobeNewsWire · Mon, 14 Sep 2026 16:01:00 -0400

Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules

Biodesix: Growing Fast While Trading Below Many Diagnostics Peers

Seeking Alpha · Thu, 10 Sep 2026 06:09:29 -0400

Biodesix is gaining momentum in lung diagnostics, with >30% revenue growth and accelerating test volumes. BDSX boasts 80%+ gross margins and improving operating leverage, supporting a credible path to profitability despite ongoing cash burn. The stock trades at a discounted EV/Sales multiple versus peers, despite industry-leading gross margins and robust clinical evidence.

Biodesix to Participate in Upcoming Investor Conferences

GlobeNewsWire · Thu, 03 Sep 2026 06:00:00 -0400

LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences:

What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now?

Zacks Investment Research · Mon, 31 Aug 2026 13:01:08 -0400

Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High?

Zacks Investment Research · Mon, 31 Aug 2026 10:56:05 -0400

The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

Zacks Investment Research · Mon, 24 Aug 2026 13:41:07 -0400

Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.

Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference

MarketBeat · Wed, 12 Aug 2026 17:05:48 -0400

Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the principal drivers of its growth strategy.

Market information is provided for research and visualization and is not investment advice.